EUVIMEDEUVIMED entdecken
Fallbericht

Cytokine release syndrome induced by dabrafenib and trametinib therapy in BRAF V600E-mutant non-small cell lung cancer

Toshiyuki Sumi iD, Taiki Ishigooka, Keigo Matsuura, Takumi Ikeda, Yuichi Yamada, Hirofumi Chiba

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyaf004 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Toshiyuki Sumi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, 38-3 Goryoukaku-cho, Hakodate, Hokkaido 040-8611, Japan. Hauptthemen laut MEDLINE: Oximes, Pyrimidinones, Pyridones, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) with BRAF V600E mutations is responsive to targeted therapies, such as dabrafenib and trametinib. However, these treatments can lead to serious adverse events, including cytokine release syndrome (CRS). Herein, we report the case of a 75-year-old man with stage IVB NSCLC and a BRAF V600E mutation who developed severe CRS, manifesting hepatic and renal dysfunction, following treatment with dabrafenib and trametinib. Despite initial fever management, the patient’s renal function deteriorated rapidly, necessitating hemodialysis. Elevated cytokine levels, including interleukin-6, interferon-γ, and tumor necrosis factor α, were detected. The patient was treated with steroid pulse therapy, which resulted in fever resolution, and his renal function gradually improved. Hemodialysis was discontinued as renal function recovered. This case underscores the importance for early recognition and management of CRS in patients receiving targeted therapies. Prompt intervention with steroids may prevent CRS progression and mitigate associated organ dysfunction. Further investigation is required to clarify the mechanisms of CRS in patients receiving targeted therapy, particularly in the absence of prior immune checkpoint inhibitor use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OximesPyrimidinonesPyridonesLung NeoplasmsProto-Oncogene Proteins B-rafCarcinoma, Non-Small-Cell LungImidazolesCytokine Release SyndromeAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAgedMutation

Stichwörter der Autor:innen

BRAF V600Ecytokine release syndromedabrafenibnon-small cell lung carcinomatrametinib

Substanzen

dabrafenibtrametinibOximesPyrimidinonesPyridonesProto-Oncogene Proteins B-rafImidazolesBRAF protein, human

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, 38-3 Goryoukaku-cho, Hakodate, Hokkaido 040-8611, Japan.
  • Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, South 1, West 17, Chuo-ku, Sapporo 060-8556, Japan.

ORCID-Profile: Toshiyuki Sumi

Zitieren

APA

Sumi, T., Ishigooka, T., Matsuura, K., Ikeda, T., Yamada, Y., & Chiba, H. (2025). Cytokine release syndrome induced by dabrafenib and trametinib therapy in BRAF V600E-mutant non-small cell lung cancer. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf004

Vancouver

Sumi T, Ishigooka T, Matsuura K, Ikeda T, Yamada Y, Chiba H. Cytokine release syndrome induced by dabrafenib and trametinib therapy in BRAF V600E-mutant non-small cell lung cancer. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf004

BibTeX
@article{Sumi2025,
  author = {Sumi, Toshiyuki and Ishigooka, Taiki and Matsuura, Keigo and Ikeda, Takumi and Yamada, Yuichi and Chiba, Hirofumi},
  title = {Cytokine release syndrome induced by dabrafenib and trametinib therapy in BRAF V600E-mutant non-small cell lung cancer},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyaf004}
}
Kostenlos starten →